SLIDE 1
IMPLICATION OF HLA ANTIBODIES & TRALI MITIGATION PROGRAM
Massimo Mangiola, Ph.D.
Director, Special Services Rhode Island Blood Center
LEARN Webinars: Management of TRALI
June 23, 2015 2:00 – 3:30 pm (EDT)
IMPLICATION OF HLA ANTIBODIES & TRALI MITIGATION PROGRAM - - PowerPoint PPT Presentation
IMPLICATION OF HLA ANTIBODIES & TRALI MITIGATION PROGRAM - - PowerPoint PPT Presentation
IMPLICATION OF HLA ANTIBODIES & TRALI MITIGATION PROGRAM Massimo Mangiola, Ph.D. Director, Special Services Rhode Island Blood Center LEARN Webinars: Management of TRALI June 23, 2015 2:00 3:30 pm (EDT) ANTIBODY PRODUCTION ANTIBODY
SLIDE 2
SLIDE 3
ANTIBODY PRODUCTION
SLIDE 4
ANTIBODY PRODUCTION
SLIDE 5
ANTIBODY RESPONSE
SLIDE 6
ANTIBODY RESPONSE
SLIDE 7
ANTIBODY CLASSES
SLIDE 8
ANTIBODY CLASSES
SLIDE 9
ANTIBODY CLASSES
SLIDE 10
WHAT TRIGGERS THE IMMUNE SYSTEM TO GENERATE HLA ANTIBODIES ?
SLIDE 11
WHAT CAN INDUCE ANTIBODY PRODUCTION ?
TRANSPLANT TRANSFUSION PREGNANCY
SLIDE 12
WHAT IS NON-SELF ON A HLA MOLECULE ?
SLIDE 13
WHAT IS NON-SELF ON A HLA MOLECULE ?
SLIDE 14
WHAT IS NON-SELF ?
SLIDE 15
HOW IS NON-SELF ON A HLA MOLECULE RECOGNIZED ?
SLIDE 16
HOW IS NON-SELF ON A HLA MOLECULE RECOGNIZED ?
SLIDE 17
ANTIBODY ½ LIFE
SLIDE 18
PREGNANCY ANTIBODY
SLIDE 19
HOW CAN HLA ANTIBODIES CAUSES TRALI ?
SLIDE 20
SLIDE 21
SLIDE 22
THE PERFECT “STORM”
SLIDE 23
THE PERFECT “STORM”
About 9µm
SLIDE 24
THE PERFECT “STORM”
SLIDE 25
THE PERFECT “STORM”
Lumen: 5.5 µm Distance from alveolus: 0.5 µm
SLIDE 26
THE PERFECT “STORM”
Lumen: 5.5 µm Distance from alveolus: 0.5 µm
SLIDE 27
THE PERFECT “STORM”
SLIDE 28
HLA ANTIBODIES & TRALI
Class I HLA antibody
ANTIBODY-DEPENDENT MODEL
Class II HLA antibody or FcγR
SLIDE 29
HLA ANTIBODIES & TRALI
1st EVENT (1ST HIT)
Recipient predisposing clinical condition resulting in the sequestration of primed neutrophils in the lungs (cytokines promote priming and adherence of neutrophils).
2nd EVENT (2ND HIT)
Transfusion of blood product(s) carrying a biological substance able to activate primed neutrophils (i.e. leukocyte antibodies, DAMPs, LysoPC, etc.)
ANTIBODY-INDEPENDENT MODEL (2 hit theory)
SLIDE 30
HOW CAN HLA ANTIBODIES BE DETECTED IN THE LABORATORY?
SLIDE 31
HLA ANTIBODY DETECTION
™DONORSCREEN HLA ASSAY
™DONORSCREEN HLA ASSAY
ANTIBODY SCREEN ASSAY
SOLID PHASE ANTIBODY SCREENING
LUMINEX SOLID PHASE
ELISA-BASED ANTIBODY SCREENING
SLIDE 32
LUMINEX SCREENING
SLIDE 33
ELISA SCREENING
INCUBATION WASH INCUBATION WASH INCUBATION STOP DETECTION
SLIDE 34
HLA ANTIBODY DETECTION
™DONORSCREEN HLA ASSAY
™DONORSCREEN HLA ASSAY
ANTIBODY SCREEN ASSAY
SOLID PHASE ANTIBODY SCREENING
LUMINEX SOLID PHASE
ELISA-BASED ANTIBODY SCREENING
SLIDE 35
RHODE ISLAND BLOOD CENTER EXPERIENCE
SLIDE 36
TRALI MITIGATION TIMELINE
CDC Screening Luminex Solid Phase ELISA (DonorScreen HLA)
ABC releases statement to encourage considering TRALI reduction strategies First AABB bulletin on TRALI ~1998 - 2002 2002 2004 2006 2008 - present 2016 AABB Standard 5.4.1.2 to be implemented
SLIDE 37
0-20(0.5%) 21-40 22% 41-60 56.5% >60 21%
THE RIBC EXPERIENCE
RIBC Donor Population Age groups
High volume plasma donors 36,952 previously pregnant female Data Range: 2008 to April 2015
SLIDE 38
THE RIBC EXPERIENCE
10000 20000 30000 40000 FEMALE BLOOD DONORS 36952 23823 13129 (35.5%) TOTAL NEGATIVE POSITIVE
Data Range: 2008 to April 2015
SLIDE 39
0-20
(0.4%) Positive Negative
41-60
(59.3%)
>60
(17.3%)
21-40
(23%)
THE RIBC EXPERIENCE
High volume plasma donors 36,952 previously pregnant female 23, 823 negative for HLA antibodies 13,129 positive for HLA antibodies Data Range: 2008 to April 2015
SLIDE 40
0-20 (28%) 21-40 (36.5%) 41-60 (36.9%) >60 (28.8%)
Positive Negative
THE RIBC EXPERIENCE
High volume plasma donors Rate of positive donors Normalized data by age group Data Range: 2008 to April 2015
SLIDE 41
SUMMARY
TRALI is the leading cause of transfusion-related fatalities HLA antibodies can induce TRALI in sensitized recipients HLA pregnancy antibodies can disappear overtime HLA antibodies detection can be done by Luminex or ELISA solid phase RIBC TRALI Mitigation program started around 1998. Since then, only ~400 TRALI investigation have been done. Of these, only 5% had HLA antibodies in the donor sample and just a handful of cases may be due to reverse-TRALI. Donor age is NOT a factor; number of pregnancies may be more relevant
SLIDE 42
CONCLUSION
Mitigation proves to be effective in reducing TRALI occurrence An action plan must be in place by October 1st, 2016
SLIDE 43
CONCLUSION
Mitigation proves to be effective in reducing TRALI occurrence An action plan must be in place by October 1st, 2016
SLIDE 44
CONCLUSION
Should positive donors be re-screened and when ? If a donor is still positive after re-screen, should testing be repeated ? testing frequency ? for how long to re-test ? Because age of donor does not seems to be a factor, changes in recruitment strategies may not help in decreasing the positive rate. Can PAS help us in re-entry of some aphaeresis donor ? How do we establish which donor to re-entry with PAS ? Should we consider transfusion risk ? What about HNA antibody screening ? What else ?
SLIDE 45
LEARN Webinars: Management of TRALI
May 21, 2015 2:00 – 3:30 pm (EDT)